Chengwu Zeng[Author] - Search Results

Year	Number of Results
2011	2
2012	1
2014	5
2015	3
2016	2
2017	1
2018	4
2019	2
2020	5
2021	9
2022	11
2023	9
2024	2

1

Roles of METTL3 in cancer: mechanisms and therapeutic targeting.

Zeng C, Huang W, Li Y, Weng H. Zeng C, et al. J Hematol Oncol. 2020 Aug 27;13(1):117. doi: 10.1186/s13045-020-00951-w. J Hematol Oncol. 2020. PMID: 32854717 Free PMC article. Review.

2

Targeting NRF2 uncovered an intrinsic susceptibility of acute myeloid leukemia cells to ferroptosis.

Liu X, Zhong S, Qiu K, Chen X, Wu W, Zheng J, Liu Y, Wu H, Fan S, Nie D, Wang X, Yu Z, Liao Z, Zhong M, Li Y, Zeng C. Liu X, et al. Among authors: zeng c. Exp Hematol Oncol. 2023 May 17;12(1):47. doi: 10.1186/s40164-023-00411-4. Exp Hematol Oncol. 2023. PMID: 37198609 Free PMC article.

3

Current insight into the regulation of PD-L1 in cancer.

Liu Z, Yu X, Xu L, Li Y, Zeng C. Liu Z, et al. Among authors: zeng c. Exp Hematol Oncol. 2022 Jul 30;11(1):44. doi: 10.1186/s40164-022-00297-8. Exp Hematol Oncol. 2022. PMID: 35907881 Free PMC article. Review.

4

TIM-3 in Leukemia; Immune Response and Beyond.

Rezaei M, Tan J, Zeng C, Li Y, Ganjalikhani-Hakemi M. Rezaei M, et al. Among authors: zeng c. Front Oncol. 2021 Sep 30;11:753677. doi: 10.3389/fonc.2021.753677. eCollection 2021. Front Oncol. 2021. PMID: 34660319 Free PMC article. Review.

5

BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia.

Zhong M, Gao R, Zhao R, Huang Y, Chen C, Li K, Yu X, Nie D, Chen Z, Liu X, Liu Z, Chen S, Lu Y, Yu Z, Wang L, Li P, Zeng C, Li Y. Zhong M, et al. Among authors: zeng c. Cell Death Dis. 2022 Aug 2;13(8):671. doi: 10.1038/s41419-022-05123-x. Cell Death Dis. 2022. PMID: 35918330 Free PMC article.

6

Disulfiram, an aldehyde dehydrogenase inhibitor, works as a potent drug against sepsis and cancer via NETosis, pyroptosis, apoptosis, ferroptosis, and cuproptosis.

Nie D, Chen C, Li Y, Zeng C. Nie D, et al. Among authors: zeng c. Blood Sci. 2022 Jul 1;4(3):152-154. doi: 10.1097/BS9.0000000000000117. eCollection 2022 Jul. Blood Sci. 2022. PMID: 36518588 Free PMC article. Review.

7

The role of NFAT in the pathogenesis and targeted therapy of hematological malignancies.

Gao R, Zhang Y, Zeng C, Li Y. Gao R, et al. Among authors: zeng c. Eur J Pharmacol. 2022 Apr 15;921:174889. doi: 10.1016/j.ejphar.2022.174889. Epub 2022 Mar 12. Eur J Pharmacol. 2022. PMID: 35288191 Review.

8

Regulation of PD-1 in T cells for cancer immunotherapy.

Yu X, Gao R, Li Y, Zeng C. Yu X, et al. Among authors: zeng c. Eur J Pharmacol. 2020 Aug 15;881:173240. doi: 10.1016/j.ejphar.2020.173240. Epub 2020 Jun 1. Eur J Pharmacol. 2020. PMID: 32497624 Review.

9

[Research Advances in the Mechanisms of BRD4 and Its Inhibitors in Hematologic Malignancies--Review].

Gao RL, Zeng CW, Li YQ. Gao RL, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021 Aug;29(4):1365-1368. doi: 10.19746/j.cnki.issn.1009-2137.2021.04.057. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021. PMID: 34362532 Review. Chinese.

10

CASP1 is a target for combination therapy in pancreatic cancer.

Wang X, Chen Z, Nie D, Zeng X, Zhong M, Liu X, Zhong S, Wang L, Liao Z, Chen C, Li Y, Zeng C. Wang X, et al. Among authors: zeng c. Eur J Pharmacol. 2023 Dec 15;961:176175. doi: 10.1016/j.ejphar.2023.176175. Epub 2023 Nov 8. Eur J Pharmacol. 2023. PMID: 37949157

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

50 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Results by year